5 Best Least Shorted Stocks to Buy Now

This article presents an overview of the 5 Best Least Shorted Stocks to Buy Now. For a detailed overview of such stocks, read our article, 15 Best Least Shorted Stocks to Buy Now.

5. Eli Lilly And Co (NYSE:LLY)

Number of Hedge Fund Investors: 102

BofA recently published its Growth 10 list for February. The list includes stocks with strong EPS growth and Buy ratings. Eli Lilly And Co (NYSE:LLY) is part of the list.

A total of 102 hedge funds tracked by Insider Monkey had stakes in Eli Lilly And Co (NYSE:LLY). The most notable hedge fund stakeholder of  Eli Lilly And Co (NYSE:LLY) during this period was Ken Fisher’s Fisher Asset Management which owns a $2.4 billion stake in Eli Lilly And Co (NYSE:LLY).

Baron Health Care Fund stated the following regarding Eli Lilly and Company (NYSE:LLY) in its fourth quarter 2023 investor letter:

“Stock selection was also positive in the sub-industry owing to strong gains from therapeutics-focused pharmaceutical giant Eli Lilly and Company (NYSE:LLY). Lilly’s stock continued to outperform driven by strong sales of blockbuster diabetes medicine Mounjaro and ongoing enthusiasm surrounding the company’s obesity and diabetes franchises, particularly after Novo Nordisk released its SELECT trial results showing a 20% relative risk reduction in overweight patients with cardiovascular disease and no prior history of diabetes.

Eli Lilly and Company is a global pharmaceutical company that discovers, develops, manufactures, and sells medicines in the categories of diabetes, oncology, neuroscience, and immunology, among other areas. Stock performance was strong due to strong third quarter sales of blockbuster diabetes medicine Mounjaro and ongoing enthusiasm surrounding the company’s obesity and diabetes franchises. We continue to think Lilly is well positioned to grow revenue and earnings at attractive rates through the end of the decade and beyond.

We own Eli Lilly and Company, which we believe will remain a leader in the GLP-1 medicine class with Mounjaro, Zepbound, and the company’s deep pipeline of next generation GLP-1 medicines.”